Patient preferences regarding the use of combination **ERA+PDE5i for the treatment of pulmonary arterial** hypertension: Results from a discrete choice experiment.

Melisa Wilson¹, Nicholas A Kolaitis², Martha Kingman³, Gabriela Gomez Rendon⁴, David Lopez⁴, Mohammad Rahman⁴, Carly J Paoli⁴, Ashley Martin⁵, November McGarvey⁵, Abraham Lee⁵, Sana Mirza⁵, Lana Melendres-Groves⁶

¹Advanced Lung Disease, AdventHealth Medical Group, Orlando, FL, USA; ²Department of Pulmonary and Critical Care Medicine, The University of California, San Francisco Medical Center, San Francisco, CA, USA; ³ University of Texas Southwestern Medical Center, Dallas, Texas, USA (Retired); ⁴ Actelion Pharmaceuticals US, Inc., Titusville, New Jersey; ⁵ BluePath Solutions, Los Angeles, CA, USA; ⁶ Division of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, NM, USA.

Background

- Upfront combination therapy with ERA+PDE5i is the standard of care for patients with pulmonary arterial hypertension (PAH) due to improved patient outcomes.^{1,2}
- Despite guidelines, many continue to be treated with monotherapy at 6-months postinitiation.^{2,3}
- Reasons for this disconnect in real-world vs. recommended prescribing practices are unclear.
- In this study, we examined treatment-level attributes affecting patients' perceptions and willingness to adopt dual combination of ERA+PDE5i.
- We also explored if a single tablet combination therapy (STCT) might provide additional benefits and enhance patient participation in treatment choices.

Methods

- This was an online survey of N=201 self-reported PAH patients in the US from PHAR, the largest active longitudinal registry tracking PAH patients across the country.
- Patient must have used an oral PAH medication for 3+ months in the past year
- Patient with a self-reported diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), interstitial lung disease (ILD), or diastolic heart failure were excluded
- Seven attributes associated with ERA+PDE5i therapy were explored as part of a discrete choice experiment (DCE) to assess patients' willingness to adopt ERA+PDE5i (Table 1).
- Attributes and levels were obtained via literature review and input from clinical advisors.
- Additional exploration of STCT on ERA-PDE5i acceptance was assessed via supplemental questionnaire.

Table 1. Treatment Attributes and Levels in the DCE

Attribute	Level 1	Level 2	Level 3	Level 4	
Out-of-pocket costs	<\$20	\$20-\$50	\$50-\$100	\$100-\$200	
Dosing Frequency	One pill, once daily	Three pills, multiple times a day	Four pills, multiple times a day	Ten to thirteen pills, multiple times a day	
Discontinuation due to side effects*	7% of patients	8% of patients	9% of patients	12% of patients	
Prior authorization	Requires 1 prior authorization	Requires 2 prior authorizations	NA	NA	
Pharmacies	Requires 1 pharmacy	Requires 2 pharmacies	NA	NA	
Dose increase (titration)	2 steps to reach goal dose	3 steps to reach goal dose	4-5 steps to reach goal dose	NA	
Patient support program	Available	Not available	NA	NA	

Selected attributes and levels were obtained via literature review and input from clinical advisors. * Presented to respondents in the DCE as "the percentage of patients that stopped medication due to side effects" We utilized adaptive choice-based conjoint analysis methodology to ask patients to select the treatment profile they found most attractive (see **Table 2** for an example choice trial).

- These iterative choice trials calculated preference weights (PW) for each individual level for each attribute measured. These preference weights were used to calculate the relative importance of each attribute.
- Larger differences across preference weights within a single attribute indicated greater influence in shaping patients' willingness to adopt ERA+PDE5i.
- Relative importance scores summarized the most/least influential attributes driving patients' willingness to adopt ERA+PDE5i.
- Patient characteristics and attitudinal beliefs were analyzed descriptively and in aggregate across the total sample

Table 2. Example of a Choice Task From the DCE

Therapy characteristics	Therapy A	Therapy B	Therapy
Out-of-Pocket Costs	<\$25	\$50-100	\$50-10
Dosing	One pill, once daily	Three pills, multiple times a day	Ten to thirteen pills, a day
Prior Authorizations	Requires 1 prior authorization	Requires 2 prior authorizations	Requires 1 prior a
Pharmacies	Requires 1 pharmacy	Requires 1 pharmacy	Requires 2 ph
Discontinuation Due to Side Effects	8%	7%	9%
Dose Increase	2 steps to reach goal dose	3 steps to reach goal dose	4-5 steps to read
Patient Support Program	Available	Available	Not availa

Presented at the 2024 PHA International PH Conference Aug. 15-18, 2024; Indianapolis, IN, USA

Results • Respondents were primarily White (86.1%) and female (88.6%). A majority were not employed (70.2%), with over one-third reporting a disability (38.3%). The most common regimens at the time of the survey were triple therapy PDE5i+ERA+prostacyclin (36.8%), double therapy PDE5i+ERA (17.9%), and monotherapy PDE5i (15.4%). (Table 3). **Table 3. Patient Characteristics Characteristic** Sex, n (%) Female Race, n (%) White Black or African American Native Hawaiian or Other Pacific Islander Two or More Races Prefer Not to Answer Employment, n (%) Employed full time Self-employed Employed part time Manage family / household Not employed and looking for work Not employed and not looking for work (e.g., student) Not employed and unable to work (e.g., disability) Prefer not to answer Current Treatment*, n (%) PDE5i + ERA + prostacyclin PDE5i + ERA PDE5i monotherapy ERA monotherapy Other sGC + ERA + prostacyclin sGC + ERA Time Since Diagnosis, years Mean (SD) Median (Range) *PDE5i (sildenafil or tadalafil); ERA (bosentan, ambrisentan, or macitentan); prostacyclin (selexipag, treprostinil, epoprostenol, or iloprost); sGC (riociguat) SD; standard deviation Level 5 \$200+ Fig 1. Relative Importance Scores of Each Attribute The 2 most important factors influencing ERA+PDE5i NA adoption were the out-of-pocket costs (33.7) and NA dosing frequency (31.5) (Figure 1). Out-of-pocket costs NA Individual preference weights confirmed that patients NA Dosing frequency were most accepting of ERA+PDE5i therapies when NA available at the lowest out-of-pocket cost and the _____ Patient support program NA least frequent dosing regimen (i.e., 1 pill, once daily) Discontinuation due to (Figure 2). side effects* • Availability of patient support programs, discontinuation Pharmacies due to side effects, number of pharmacies, number of prior authorizations, and dose increase (titration) were Prior authorization less important. Dose increase (titration) 5.0 **Fig 2. Individual Preference Weights – Top 2 Attributes*** 113.7 105.9 69.0 24.6 -20.6 -71.8 -115.5 100 ls, multiple times authorization harmacies each goal dose ilable


REFERENCES:


- Klinger et al. Chest. 2019;155(3):565-86.
- 2. Humbert et al., European Heart Journal. 2022; 43(38):3618-731

Dosing Frequency

3. Benza et al., Chest. 2019; 156(2):323-337. 4. Sitbon et al. *Eur Respir J*. 2020 Sep 3;56(3)

N=201	
170 (00 0)	
178 (88.6)	
173 (86.1)	
10 (5.0)	
6 (3.0)	
1 (0.5)	
5 (2.5)	
6 (3.0)	
35 (17.4)	
11 (5.5)	
14 (7.0)	
21 (10.5)	
3 (1.5)	
33 (16.4)	
77 (38.3)	
7 (3.5)	
74 (36.8)	
36 (17.9)	
31 (15.4)	
22 (11.0)	
16 (8.0)	
15 (7.5)	
7 (3.5)	
10.6 (8.0)	
9 (1 – 38)	
ipag, treprostinil, epoprostenol, or iloprost); sGC (riociguat)	






Blinded Choice of PAH Therapies

- blinded (unlabeled) treatment profiles (Table 4).

Fig. 3 Blinded Choice Exercise – STCT Preference



Treatment Profiles Shown	Treatment A	Treatment B	Treatment C	Treatment D
Dosing frequency	1 tablet once daily	3 tablets per day	Up to 10-13 tablets per day	Up to 3 tablets per day
Dose increase (titration)	Available	Available	Available	Available
Discontinuation due to side effects ⁴⁻⁶	8%	7%	9%	12%
Pharmacies required	Requires 1 pharmacy	Requires 2 pharmacies	Requires 2 pharmacies	Requires 2 pharmacies
Prior authorizations	Requires 1 prior authorization	Requires 2 prior authorizations	Requires 2 prior authorizations	Requires 2 prior authorizations

Presented to respondents in the DCE as "the percentage of patients that stopped medication due to side effects. ** Assumes max dose of 60-80 mg sildenafil.

Perceptions of a STCT for ERA+PDE5i adoption

- burden (37.3%)
- adherence (39.3%) (Figure 4b).

Fig 4a. Perceptions of STCT – Pros

- I might be able to take fewer doses of my medication each day
- I would find it easier to remember when to take my medication and stick to my medication schedule

I would be able to take less pills

Fig 4b. Influence of STCT on treatment behavior

Would have started therapy sooner

Would result in less missed doses

5. Jansa & Pulido, *Am J Cardiovasc Drugs*. 2018 Feb;18(1) 6. Galiè et al., N Engl J Med. 2015 Aug 27;373(9)

Key Takeaway

2

Patients prefer a single-tablet combination therapy (STCT) over traditional multi-pill regimens, mostly due to its ability to streamline their prescriptions and reduce pill burden. Costs remain a significant factor in determining whether patients can afford the convenience an STCT offers.

After each DCE trial, patients were asked to select their preferred therapy from an array of four

Patients displayed an overwhelming preference for a STCT of macitentan-tadalafil (96.0%) over alternative traditional "loose dose" profiles (<5%) (Figure 3).

96.0%

Macitentan + Sildenafil Loose Dose Combo Macitentan + Tadalafil Fixed-Dose Combo (STCT)

Table 4. Blinded Choice Exercise – STCT Preference

Results from a supplemental questionnaire confirmed that most patients believed that a STCT would reduce pill consumption (83.1%) and time spent managing prescriptions (68.7%) (Figure 4a). • Over one-third of patients identified benefits to compliance (42.3%), cost (39.8%), and dose

Approximately a third of patients reported benefits to treatment initiation (34.8%) followed by

37.3%

39.8%

42.3%

68.7%

83.1%

I might spend less money on my medication I could spend less time managing my prescriptions

> 34.8% 39.3%

Funding: Actelion Pharmaceuticals US, Inc., Titusville, New Jersey, USA.

Disclosures: <u>G Gomez, D Lopez, M Northup, C Paoli, M Rahman</u>: Employees of Johnson & Johnson (J&J) and hold stock in J&J. <u>A Martin, A Lee, N</u> McGarvey: Employees of BluePath Solutions (BPS). N Kolaitis: Has received financial support from J&J, Liquidia, United Therapeutics, Bayer. M Wilson: Has received financial support from J&J, Merck, Bayer, United Therapeutics. <u>M Kingman</u>: Has received financial support from Aerami, Merck, J&J, Liquidia, Gossamer. <u>L Melendres</u>: Has received financial support from J&J, United Therapeutic, Bayer, Merck.